RecruitingNot ApplicableNCT06039644

To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer

To Evaluate the Efficacy of Probiotics in Improvement and Prevention of Chemotherapy Associated Side Effectes in Patients With the Breast Cancer

Sponsor

GenMont Biotech Incorporation

Enrollment

100 participants

Start Date

Apr 8, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

Eligibility

Min Age: 20 YearsMax Age: 80 Years

Inclusion Criteria4

Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery)
BMI \> 18 kg/m\^2
Age between 20 and 80 years old
Patients judged by physicians to participate in this trial and who are willing

Exclusion Criteria5

Pregnant or lactating female patients
Patients with bariatric surgery, gastrointestinal resections, Crohn's disease, celiac disease
BMI \< 18 kg/m\^2
Patient who have severe allergy to soybeans or peanuts
Those who are under 20 years old or over 80 years old

Interventions

DIETARY_SUPPLEMENTProbiotic

Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).

OTHERPlacebo

Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.